Cannabinoid

MJ Unpacked Announces Esteemed Researcher Dedi Meiri, Ph.D., as Keynote Speaker, Highlighting Groundbreaking Cannabis Research

Retrieved on: 
Wednesday, March 13, 2024
Emerald, Poseidon, Epilepsy, Cannabinoid, Growth, Learning, Science, Associate, Diabetes, Cancer, Role, MJ, Cannabis, Community engagement, Rise, Drug

ATLANTIC CITY, N.J., March 13, 2024 /PRNewswire/ -- MJ Unpacked, the only national cannabis event with attendance open exclusively to cannabis industry operators and investors, is thrilled to announce Dedi Meiri, Ph.D. as the keynote speaker for its upcoming event on the East Coast. Taking place at the Hard Rock Hotel Casino in Atlantic City, NJ, from April 9th to 11th, the event is poised to address critical industry topics, including cannabis rescheduling, the evolution of hemp-derived cannabinoids, and the imperative of community engagement in cannabis research.

Key Points: 
  • Scheduled for Tuesday, April 9th, Dr. Meiri's keynote will spotlight the transformative potential of cannabis research.
  • His groundbreaking work, supported by a team of 44 researchers, seeks to align cannabis treatments with precise medical needs, contributing significantly to the global understanding of cannabis' benefits.
  • Kim Jage, co-founder of MJ Unpacked and Jage Media, expressed excitement about Dr. Meiri's participation: "Having Dr. Dedi Meiri, a globally recognized researcher, as our keynote speaker emphasizes our dedication to fostering a deep understanding of cannabis' potential.
  • MJ Unpacked is committed to serving as the premier convening point for cannabis industry leaders, providing unparalleled opportunities for learning, networking, and growth.

Real Isolates and Sanctuary Medicinals Announce Launch of Smokenol™-Infused Product Lines

Retrieved on: 
Tuesday, March 12, 2024
Temperature, Cannabinoid, Science, Partnership, Patient, Research, Smoke, Smoking, Medicinals, THC, Sanctuary, Medicinal plants

WOBURN, Mass., March 12, 2024 /PRNewswire/ -- Sanctuary Medicinals is pleased to announce an exciting new partnership with Real Isolates, utilizing their patented Smokenol™ cannabis smoke extraction process for infusion in select Sanctuary products.

Key Points: 
  • WOBURN, Mass., March 12, 2024 /PRNewswire/ -- Sanctuary Medicinals is pleased to announce an exciting new partnership with Real Isolates, utilizing their patented Smokenol™ cannabis smoke extraction process for infusion in select Sanctuary products.
  • Partnering with Real Isolates is a perfect example of that commitment.
  • Co-Founder of Real Isolates, Andy Westerkamp, explains "Real Isolates and Sanctuary Medicinals prioritize quality of life for patients and consumers.
  • Alex Hildrith, Laboratory Director for Sanctuary adds, "Sanctuary's lab team is very excited to announce our official partnership with Real Isolates.

InvestmentPitch Media Video Discusses StickIt Technologies and its Portfolio of Products Bringing New Enhanced Experiences to Consumers Smoking or Drinking Various Products

Retrieved on: 
Tuesday, March 12, 2024
Smoking, News, Cannabinoid, Terpene, Drinking, CBG, THC, Cannabis, Research, Drug

Vancouver, British Columbia--(Newsfile Corp. - March 12, 2024) - InvestmentPitch Media video features StickIt Technologies (CSE: STKT), a company at the forefront of the global cannabis industry with a portfolio of revolutionary products that bring new enhanced experiences to consumers smoking or drinking various products.

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - March 12, 2024) - InvestmentPitch Media video features StickIt Technologies (CSE: STKT), a company at the forefront of the global cannabis industry with a portfolio of revolutionary products that bring new enhanced experiences to consumers smoking or drinking various products.
  • For more information, please view the InvestmentPitch Media video which provides additional information about this news and the company.
  • SipIt, another new product, is a special straw containing a hidden cartridge containing cannabinoids such as THC and CBD.
  • For more information, please visit the company's website www.stickit-labs.com , contact Eli Ben-Haroosh, CEO, by email at [email protected] .

StrainsForPains, Inc. Discusses Inspiration, App Technology and CBD Market Entrance with The Stock Day Podcast

Retrieved on: 
Thursday, February 29, 2024
Pet, Anxiety, Parkinson's disease, Intelligence, Traction, Chemical oxygen demand, DSM-IV codes, Quality of life, Cancer, MIT, Pain, OTC Markets Group, State, Database, Cannabinoid, State university system, International Cannabinoid Research Society, Chronic pain, Business, SUNY, Depression, CBD, Patient, Medicine, Osteoarthritis, Pharmacotherapy, Movement, Interview, Insomnia, Cannabis, Research, Alzheimer's disease

I financed and worked with Olivia Newton-John's Koala Blue in the 1980's and Richard Diehl's Graphsoft (now Vectorworks) in the 1990's.

Key Points: 
  • I financed and worked with Olivia Newton-John's Koala Blue in the 1980's and Richard Diehl's Graphsoft (now Vectorworks) in the 1990's.
  • I developed regenerative medicine systems with stem cell technology in the 1980's working on umbilical cord therapy to treat genetic diseases, cancers, and inherited disorders.
  • In 2024 we will focus our efforts on the development of our upcoming advanced AI app and our CBD brand that will expand into many products.
  • We will seek to forge a new path in our approach to healthcare, that will expand to CBD products for pets as well as a nutritional app.

Can B Corp. Secures Ownership and Control of Two Cannabis Patents Valued at $122 Million and Potentially in Excess of $750 Million

Retrieved on: 
Monday, March 11, 2024
OTCQB, Cancer, Anxiety, THCA, Shikimate pathway, Growth, CBN, Cannabinoid, European, Health, Ground substance, Chronic pain, Patent, Federal court, THC, PTSD, Cannabis, Sleep, IBS, Controlled Substances Act, Pharmaceutical industry

HICKSVILLE, NY, March 11, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Can B Corp., a Florida corporation (OTCQB: CANB) (“Can B”), a health and wellness company specializing in developing, producing and selling hemp-derived cannabinoid products, is pleased to announce that it has secured ownership and control of two cannabis patents that were valued at $122 million, applying a 90% discount and assuming a revenue stream through August 2034, and further based on only CBD claims and only in the U.S. It is believed that if the global THC and CBD markets were added to the valuation, then the value of the patents is potentially up to $750 million.

Key Points: 
  • It is believed that if the global THC and CBD markets were added to the valuation, then the value of the patents is potentially up to $750 million.
  • These patents were previously awarded to United Cannabis Corporation and recently assigned to Can B by a court procedure.
  • The patents were valued at $122 million in December 2020 by an independent third-party valuation team, which used a 90% discount rate due to the emerging nature of the industry.
  • We believe there is a strong opportunity to monetize these patents as they represent important innovations in this industry.

SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe

Retrieved on: 
Thursday, March 7, 2024
Central nervous system, TEL, Patent, Cannabinoid, Safety, Disorder, Pharmaceutical industry

TEL AVIV, Israel, March 07, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that the process of granting and validation for its core-technology patent has been completed in certain European countries. This patent covers combinations of cannabinoids and n-acylethanolamines (the “Patent”). The Patent aligns seamlessly with the Company's proprietary technology designed to enhance the safety of cannabinoids by using low dosages of active components while maintaining their therapeutic benefits.

Key Points: 
  • This patent covers combinations of cannabinoids and n-acylethanolamines (the “Patent”).
  • The Patent aligns seamlessly with the Company's proprietary technology designed to enhance the safety of cannabinoids by using low dosages of active components while maintaining their therapeutic benefits.
  • The Patent was granted and validated in Austria, Belgium, Denmark, France, Germany, Ireland, Italy, Netherlands, Norway, Poland, Spain, Sweden, Switzerland, Liechtenstein and the United Kingdom.
  • This grant adds to the patent portfolio of the Company, thereby supporting the innovation of SciSparc’s technologies.

MariMed’s Betty’s Eddies™ Introduces Ache Away Eddies PM For Those Who Chews A Pain-Free Night’s Sleep

Retrieved on: 
Monday, March 4, 2024
Love, Marketing, Research, Inflammation, Pain, Sleep, CBN, Cannabinoid, Vegetable, Chamomile, CBC, Immunity, Cannabis, Transformer

NORWOOD, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Betty’s Eddies ™, the all-natural cannabis fruit chews handcrafted to fit a variety of needs, has launched a new flavor for consumers who want a pain-free, deep sleep: Ache Away Eddies PM.

Key Points: 
  • NORWOOD, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Betty’s Eddies ™, the all-natural cannabis fruit chews handcrafted to fit a variety of needs, has launched a new flavor for consumers who want a pain-free, deep sleep: Ache Away Eddies PM.
  • Ache Away Eddies PM may help ease inflammation and provide a restful night’s sleep by combining full spectrum cannabis with the most effective supporting cannabinoids and herbal supplements found in two of Betty’s Eddies best-selling fruit chews, Bedtime Betty's and Ache Away Eddies.
  • The blend of organic fruits and vegetables, CBN, CBC, Chamomile, Turmeric, and Piperine means sleeping is no longer a pain for those who chews the fast-acting and orange creme-flavored Ache Away Eddies PM.
  • Consumers can visit the Store Locator at www.bettyseddies.com to see where they can purchase Ache Away Eddies PM and the entire Betty’s Eddies line-up.

Cronos Group Reports 2023 Fourth Quarter and Full-Year Results¹

Retrieved on: 
Thursday, February 29, 2024
Shekel, Vii, Peace, Pressure, Research, Investment, Flower, Average cost, Growth, CBN, Sale, Cannabinoid, Wind, Capital expenditure, Genetics, CBG, GMO, Edible, Patient, CBD, Tax, CBC, Capital, Cannabinol, Lord, Bank statement, Depreciation, Drug

In Israel, Cronos launched three new flower offerings under the Peace Naturals® brand in the fourth quarter, Rockstar, Dancehall, and Sonic Fuel.

Key Points: 
  • In Israel, Cronos launched three new flower offerings under the Peace Naturals® brand in the fourth quarter, Rockstar, Dancehall, and Sonic Fuel.
  • Cronos GrowCo reported to the Company preliminary unaudited net revenue to licensed producers excluding sales to the Company in the fourth quarter and full-year 2023 of approximately $6.6 million and $19.6 million, respectively.
  • In addition to principal repayment, Cronos also received approximately $10.3 million in interest payments from GrowCo in 2023, resulting in a total of approximately $15.9 million in cash payments to Cronos in 2023.
  • ET to discuss 2023 Fourth Quarter and Full-Year business results.

Hemp, Inc. Reports: Hemp-Based Foods Market Set to Reach $8.36 Billion by 2028

Retrieved on: 
Thursday, February 22, 2024
Paper, Anxiety, Restaurant, Dicarboxylic acid, CBGA, Absorption, OTC, News, Growth, Plant, CBN, Gamma-Linolenic acid, Cannabinoid, Food, Cellulose, Seed, Relaxation, Health, Clothing, Cheese, CBG, LCM, Report, Supermarket, Coffee, Textile, Oil, MCT, Paint, Cannabis, CBDA, Water

The hemp-based foods market is set to reach $8.36 billion by 2028 according to The Business Research Company’s (TBRC) latest report , “Hemp Based Foods Global Market Report 2024”.

Key Points: 
  • The hemp-based foods market is set to reach $8.36 billion by 2028 according to The Business Research Company’s (TBRC) latest report , “Hemp Based Foods Global Market Report 2024”.
  • Projected to achieve a robust compound annual growth rate (CAGR) of 8.9%, the market is anticipated to burgeon from its current standing to an impressive $8.36 billion by 2028.
  • The report highlights hemp milk, hemp oil, hemp cheese substitutes, and hemp-based protein powders as key products fueling the market's growth.
  • Distributed primarily through supermarkets and convenience stores, hemp-based foods are becoming increasingly accessible to consumers worldwide, further propelling market growth.

National Animal Supplement Council Announces Publication of Landmark Safety Study of Cannabidiol Products in Healthy Dogs

Retrieved on: 
Tuesday, March 5, 2024
Cannabis, Retail, White House, Federal Government, Pets, State, Local, Research, Other Policy Issues, Convenience Store, Consumer, Discount, Variety, Science, Veterinary, Public Policy, Government, General Health, Natural Resources, Other Retail, Health, Specialty, Doctor of Philosophy, DVM, SCI, Animal, Female, Dog, Veterinary medicine, Cannabinoid, Veterinarian, NASC, Risk, Frontiers, Cornell College, Human, Male, Cannabidiol, Dietary supplement

The National Animal Supplement Council (NASC) today announced that Frontiers in Veterinary Science (Front.

Key Points: 
  • The National Animal Supplement Council (NASC) today announced that Frontiers in Veterinary Science (Front.
  • has published results from the first-of-its-kind peer-reviewed safety study of cannabidiol products in healthy dogs.
  • In the study, different cannabinoids were well tolerated in healthy male and female dogs when dosed for 90 consecutive days with a 14-day recovery period.
  • “These data demonstrate that different cannabidiols are safe for long-term use in healthy dogs when given at the dose studied,” said Bill Bookout, NASC President.